Abstract 533P
Background
Docetaxel (DTX) + ramucirumab (RAM) is one of the standard treatment options in second-line setting after first-line platinum-based chemotherapy plus ICI. The SCORPION study, phase II trial evaluating the efficacy and safety of DTX plus RAM after first-line platinum-based chemotherapy plus ICI, demonstrated encouraging antitumor activity with a manageable safety profile. However, the clinical benefit of RAM in elderly patients is not fully elucidated. Here, we report the subset analysis of the elderly patients in SCORPION study.
Methods
The primary end point of the study was objective response rate (ORR), and secondary endpoints were disease control rate (DCR), progression-free survival (PFS), and safety etc. Patients were treated with 60 mg/m2 of DTX and 10 mg/kg of RAM on day 1 with strong recommendation of pegfilgrastim on day 2 every 3 weeks.
Results
Thirty-three patients were recruited from 8 institutions. Median age (range) was 66 (42–79) y, 15 patients (45%) were aged ≤ 65, while 6 (18%) were aged ≥ 75. As previously reported, the primary endpoint was met as 11 of 32 patients achieved PR with ORR at 34.4% (80%CI, 23.1-47.2), and median PFS was 6.5 months. In elderly patients with aged ≥ 75 years, the ORR and disease control rate were 16.7 % and 100%, respectively (1 in 6 pts had a PR and all 6 pts had their disease controlled). Median PFS was 8.5 months. No treatment-related deaths and no new safety signals were observed in elderly patients aged ≥ 75 years.
Conclusions
DTX plus RAM showed favorable DCR with 8.5 months of PFS in elderly patients aged ≥ 75 years. Although our analysis was based on small subset, DTX plus RAM could be a treatment option even in elderly patients who failed first-line platinum-based chemotherapy plus ICI.
Clinical trial identification
jRCTs041190077.
Editorial acknowledgement
Legal entity responsible for the study
Masahiro Morise.
Funding
Eli Lilly Japan K.K.
Disclosure
T. Yamaguchi: Financial Interests, Personal, Speaker’s Bureau: Ono Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, AstraZeneca, MSD, Bristol-Myers Squibbb. R. Matsuzawa: Financial Interests, Personal, Speaker’s Bureau: Boehringer Ingelheim, AstraZeneca, Pfizer, Eli Lilly, Chugai Pharmaceutical, MSD, Ono Pharmaceutical, Taiho Pharmaceutical. M. Morise: Financial Interests, Institutional, Research Grant: Boehringer Ingelheim, Eli Lilly; Financial Interests, Personal, Speaker’s Bureau: Eli Lilly, Chugai, AstraZeneca, Ono, Pfizer, MSD; Non-Financial Interests, Personal, Non financial benefits: F. Hoffmann-La Roche; Financial Interests, Institutional, Local PI: Chugai, AstraZeneca, Ono, Pfizer, Merk Serono, Kissei, Taiho, Novartis. K. Ito: Financial Interests, Personal, Speaker’s Bureau: Boehringer Ingelheim, AstraZeneca, Pfizer, Eli Lilly, Chugai Pharmaceutical, MSD, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda, Daiichi Sankyo. O. Hataji: Financial Interests, Institutional, Research Grant: AstraZeneca, Novartis, MSD, Daiichi Sankyo, Bayer Yakuhin, AbbVie, Eli Lilly, Janssen, Ono; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Chugai, Takeda, MSD, Merck, Daiichi Sankyo, Eli Lilly, AbbVie, Boehringer Ingelheim, Nippon Kayaku, Taiho. K. Takahashi: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Boehringer Ingelheim, Chugai, Eli Lilly, GSK, MSD, Nippon Kayaku, Novartis, Pfizer, Taiho, Takeda. Y. Goto: Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical CO., LTD, Nippon Boehringer Ingelheim CO., LTD., Chugai Pharmaceutical CO., LTD., Chugai Pharmaceutical CO., LTD., MSD K.K., AstraZeneca K.K., GSK K.K., Pfizer Japan Inc., Takeda Pharmaceutical CO., LTD., Nippon Kayaku Co., Ltd., Novartis Japan, Bristol Myers Squibb K.K., KYOWA HAKKO BIO CO., Ltd., Eli Lilly Japan K.K. H. Itani: Financial Interests, Personal, Speaker’s Bureau: Eli Lilly. Y. Zenke: Financial Interests, Personal, Invited Speaker: AstraZeneca, Lilly, Chugai, Boehringer Ingelheim, Ono pharmaceutical, Bristol Myers Squibb, Takeda pharmaceutical, Taiho pharmaceutical, MSD, Novartis, Nippon Kayaku, Amgen, Kyowa-Hakko Kirin; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Research Grant: AstraZeneca, MSD, Merck, Daiichi Sankyo, Amgen. M. Oki: Financial Interests, Institutional, Research Grant: AbbVie, Chugai, GSK, MSD, Parexel, Sanofi, AstraZeneca, Fujifilm Toyama Chemical, Janssen, Ono and Pfizer; Financial Interests, Personal, Speaker’s Bureau: AMCO, Canon Medical Systems, Fujifilm Toyama Chemical, Merit Medical Japan, Olympus, AstraZeneca, Chugai, Kaneka Medix, Novartis, and Sanofi. M. Ishii: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, GSK, Pfizer, Shionogi, Sanofi, Insmed, Asahi Kasei Pharma, Kyorin pharmaceutical, Chugai pharmaceutical, Boehringer Ingelheim, Eli Lilly, Daiichi Sankyo, MSD, Abbott, Taiho pharmaceutical, Amgen, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract